Pseudoprogression: an indicator for cure in combined immunotherapy?

Abstract

Pseudoprogression is a unique, uncommon phenomenon that often hints at good prognosis. To date, there has been no report of complete remission after pseudoprogression. Here, we report successful treatment of metastatic renal clear cell cancer, using anti-PD-1 antibodies combined with autologous RetroNectin-activated cytokine-induced killer cells, in two patients who were failed to multitargeted kinase inhibitors. After early pseudoprogression, complete remission was achieved. At present, one patient has stopped therapy for about 1.5 years and is still disease free.

• Authors: Lingdi Zhao, Yonghao Yang, Wei Li, Tiepeng Li, Lu Han, Hongwei Lin, Quanli Gao
• Journal: Immunotherapy (Immunotherapy) Vol. 11 Issue 13 Pg. 1087-1093 (09 2019) ISSN: 1750-7448 [Electronic] England
• PMID: 31361166 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents, Immunological
• Fibronectins
• PDCD1 protein, human
• Programmed Cell Death 1 Receptor
• Recombinant Proteins
• retronectin
• Nivolumab

Topics

• Adenocarcinoma, Clear Cell (immunology, therapy)
• Aged
• Antineoplastic Agents, Immunological (therapeutic use)
• Autografts
• Cells, Cultured
• Combined Modality Therapy
• Cytokine-Induced Killer Cells (transplantation)
• Disease Progression
• Fibronectins (immunology)
• Humans
• Immunotherapy (methods)
• Kidney Neoplasms (immunology, therapy)
• Male
• Middle Aged
• Neoplasm Metastasis
• Nivolumab (therapeutic use)
• Programmed Cell Death 1 Receptor (antagonists & inhibitors)
• Recombinant Proteins (immunology)
• Remission Induction